And research published Monday says testing millions of the middle-aged to find those who need the pricey treatment would be worth the cost, saving thousands of lives. "One of every 33 baby boomers are living with hepatitis C infection," says Dr. John...

A third study published Monday from Stanford University looked more closely at the price tag, and concluded the new triple-therapy would be cost-effective for people with advanced disease. It's still cheaper than a transplant costing well over $100,000.

"We can use the word ‘cure.' "Although not everyone will be cured, he said, clinical trials have shown major successes in reducing the level of the virus in patients and keeping it from going back up once treatment ends. The new drugs were

He was 68. His wife, Angela Davis, told the Associated Press that Davis died Friday afternoon at a Chico, Calif. , medical center after a month-long hospitalization for liver disease. Davis had been diagnosed in 2005 with Hepatitis C. In a candid...

“The benefit of these organizations and programs lies in their ability to empower people in local communities with knowledge about prevention, diagnosis and care of hepatitis C and hepatitis B,” said John Damonti, president, Bristol-Myers Squibb...

...5:32 pm Jackson cut Eastern's 12-point lead to just five near the end of the third quarter with defensive...- 12:56 am Holt and Grand Ledge hoped for a chance at an all-local Division 1 Regional wrestling final at...- 12:40 am Three-time Grammy winner Jon...

“We zullen een aantal therapeutische benaderingen verkennen voor de aanpak van deze belangrijke onvervulde medische behoefte, waaronder combinaties met andere orale antivirale middelen.” GS-7977 is een nucleotide analoge polymeraseremmer die momenteel...

Inc. (NYSE: MRK), which has a $117B market cap and as such is unlikely to get much of a boost from a single product. Clearly the hepatitis C market will be one investors need to consider for the next few years. From time to time, Streetwise Reports LLC...

As of December 31, 2009, Achillion focused on developing three Hepatitis C virus (HCV) drug candidates: ACH-1625, a protease inhibitor for the treatment of chronic hepatitis C in phase Ib clinical testing; ACH-1095, a NS4A antagonist also for the...

Gilead Sciences shares are getting hammered today after disappointing test results on one of its Hepatitis C drugs, with CNBC's Seema Mody. Related Links: Business & financial news headlines from msnbc.com Top of page

“You can’t be silent with a silent disease that has consequences like chronic hepatitis C — you need to talk to your doctor and talk to your family. Take it from me, the people who love you want to be there to help you, and want you to be there for them.”

...am Jackson cut Eastern's 12-point lead to just five near the end of the third quarter with defensive...- 12:56 am Holt and Grand Ledge hoped for a chance at an all-local Division 1 Regional wrestling final at...- 12:40 am Three-time Grammy winner Jon Secada...

...am Jackson cut Eastern's 12-point lead to just five near the end of the third quarter with defensive...- 12:56 am Holt and Grand Ledge hoped for a chance at an all-local Division 1 Regional wrestling final at...- 12:40 am Three-time Grammy winner Jon Secada...

...am Jackson cut Eastern's 12-point lead to just five near the end of the third quarter with defensive...- 12:56 am Holt and Grand Ledge hoped for a chance at an all-local Division 1 Regional wrestling final at...- 12:40 am Three-time Grammy winner Jon Secada...

...11:14 am Jackson cut Eastern's 12-point lead to just five near the end of the third quarter with defensive...- 12:56 am Holt and Grand Ledge hoped for a chance at an all-local Division 1 Regional wrestling final at...- 12:40 am Three-time Grammy winner Jon...

The results might mean the treatment “isn’t going to be enough in genotype 1 patients.” The disclosure comes as interest in Hepatitis C has accelerated rapidly. Last month, Bristol-Myers Squibb agreed to pay $2.5 billion in cash for Inhibitex, which...

ISI Group analyst Mark Schoenebaum called the clinical data "unquestionably bad news," and reduces the drug's potential in treating genotype 1 patients. He said the drug's probability of success in treating certain other genotypes remains unchanged. ...

Thank you for joining our discussion. Your comment has been posted. In order to add a comment you must click here and accept our terms and conditions. CNBC welcomes your contribution. Please respect our community and the integrity of its participants. ...

CNBC's Kayla Tausche has the story on the biotech firm finding some patients treated with its Hepatitis C drug experiencing a relapse. Related Links: Business & financial news headlines from msnbc.com Top of page